CSBio CSBio

X
[{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ulcerative Colitis Phase II Study of GSK2831781 Discontinued","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (IMP731), in patients with active ulcerative colitis. The collaboration remains in place and GSK2831781 continues to be under an exclusive license with GSK.

            Lead Product(s): IMP731

            Therapeutic Area: Gastroenterology Product Name: GSK2831781

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: GSK

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY